Loading…
Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data
Highlights • Rufinamide is an effective treatment option for Lennox–Gastaut syndrome. • Low starting doses and slow titration may improve rufinamide tolerability. • Clinical experience supports starting rufinamide at a dose of 5–10 mg/kg/day. • Real-world data show the dose can be escalated to 15–20...
Saved in:
| Published in: | Seizure (London, England) England), 2017-04, Vol.47, p.25-33 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c467t-9ef1aed48747995e63d767eda85f258511edc023f39d9735aafd85e0cdf050da3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c467t-9ef1aed48747995e63d767eda85f258511edc023f39d9735aafd85e0cdf050da3 |
| container_end_page | 33 |
| container_issue | |
| container_start_page | 25 |
| container_title | Seizure (London, England) |
| container_volume | 47 |
| creator | Kothare, Sanjeev Kluger, Gerhard Sachdeo, Rajesh Williams, Betsy Olhaye, Omar Perdomo, Carlos Bibbiani, Francesco |
| description | Highlights • Rufinamide is an effective treatment option for Lennox–Gastaut syndrome. • Low starting doses and slow titration may improve rufinamide tolerability. • Clinical experience supports starting rufinamide at a dose of 5–10 mg/kg/day. • Real-world data show the dose can be escalated to 15–20 mg/kg/day after 1–3 days. • The authors recommend not increasing rufinamide dose if no response is noted. |
| doi_str_mv | 10.1016/j.seizure.2017.02.008 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1876817062</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1059131117301267</els_id><sourcerecordid>1876817062</sourcerecordid><originalsourceid>FETCH-LOGICAL-c467t-9ef1aed48747995e63d767eda85f258511edc023f39d9735aafd85e0cdf050da3</originalsourceid><addsrcrecordid>eNqFUsuO1DAQtBCIXRY-AeQjlwQ_4tjhAFotsIw0EkjA2TJ2h_WQ2IPtsAwnLnwBf8iX4NHMcuDCySV3Vbe6qhF6SElLCe2fbNoM_vuSoGWEypawlhB1C51SwVnDeqVuV0zE0FBO6Qm6l_OGEDJ0lN9FJ0wx1ZFOnKKfL2L24RO2MWTvIJniK8JjTDgtow9mrr_YB7ytFQgl42tfrvAaQojffv_4dWlyMUvBeRdcijM8xW-vTAa8Wq1wSd5MOEFepqozwVVspuY6pslhO_ngba07U8x9dGc0U4YHx_cMfXj18v3F62b95nJ1cb5ubNfL0gwwUgOuU7KTwyCg5072EpxRYmRCCUrBWcL4yAc3SC6MGZ0SQKwbiSDO8DP0-NB3m-KXBXLRs88WpskEiEvWVMleUUl6VqniQLUp5pxg1NvkZ5N2mhK9T0Bv9DEBvU9AE6ZrAlX36Dhi-TiD-6u6sbwSnh8IUBf96iHpbKuzFpxPYIt20f93xLN_OtyY-Rl2kDdxSaG6qKnOVaDf7c9gfwVUckJZL_kfa0Wyww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1876817062</pqid></control><display><type>article</type><title>Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data</title><source>ScienceDirect Freedom Collection</source><creator>Kothare, Sanjeev ; Kluger, Gerhard ; Sachdeo, Rajesh ; Williams, Betsy ; Olhaye, Omar ; Perdomo, Carlos ; Bibbiani, Francesco</creator><creatorcontrib>Kothare, Sanjeev ; Kluger, Gerhard ; Sachdeo, Rajesh ; Williams, Betsy ; Olhaye, Omar ; Perdomo, Carlos ; Bibbiani, Francesco</creatorcontrib><description>Highlights • Rufinamide is an effective treatment option for Lennox–Gastaut syndrome. • Low starting doses and slow titration may improve rufinamide tolerability. • Clinical experience supports starting rufinamide at a dose of 5–10 mg/kg/day. • Real-world data show the dose can be escalated to 15–20 mg/kg/day after 1–3 days. • The authors recommend not increasing rufinamide dose if no response is noted.</description><identifier>ISSN: 1059-1311</identifier><identifier>EISSN: 1532-2688</identifier><identifier>DOI: 10.1016/j.seizure.2017.02.008</identifier><identifier>PMID: 28284045</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Anticonvulsants - administration & dosage ; Anticonvulsants - adverse effects ; Antiepileptic drug ; Child ; Child, Preschool ; Clinical Trials, Phase III as Topic ; Dose-Response Relationship, Drug ; Dosing ; Double-Blind Method ; Drug Administration Schedule ; Epilepsy ; Humans ; Lennox Gastaut Syndrome - drug therapy ; Lennox–Gastaut syndrome ; Neurology ; Randomized Controlled Trials as Topic ; Rufinamide ; Treatment Outcome ; Triazoles - administration & dosage ; Triazoles - adverse effects ; Young Adult</subject><ispartof>Seizure (London, England), 2017-04, Vol.47, p.25-33</ispartof><rights>The Author(s)</rights><rights>2017 The Author(s)</rights><rights>Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c467t-9ef1aed48747995e63d767eda85f258511edc023f39d9735aafd85e0cdf050da3</citedby><cites>FETCH-LOGICAL-c467t-9ef1aed48747995e63d767eda85f258511edc023f39d9735aafd85e0cdf050da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28284045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kothare, Sanjeev</creatorcontrib><creatorcontrib>Kluger, Gerhard</creatorcontrib><creatorcontrib>Sachdeo, Rajesh</creatorcontrib><creatorcontrib>Williams, Betsy</creatorcontrib><creatorcontrib>Olhaye, Omar</creatorcontrib><creatorcontrib>Perdomo, Carlos</creatorcontrib><creatorcontrib>Bibbiani, Francesco</creatorcontrib><title>Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data</title><title>Seizure (London, England)</title><addtitle>Seizure</addtitle><description>Highlights • Rufinamide is an effective treatment option for Lennox–Gastaut syndrome. • Low starting doses and slow titration may improve rufinamide tolerability. • Clinical experience supports starting rufinamide at a dose of 5–10 mg/kg/day. • Real-world data show the dose can be escalated to 15–20 mg/kg/day after 1–3 days. • The authors recommend not increasing rufinamide dose if no response is noted.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Anticonvulsants - administration & dosage</subject><subject>Anticonvulsants - adverse effects</subject><subject>Antiepileptic drug</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Dose-Response Relationship, Drug</subject><subject>Dosing</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Epilepsy</subject><subject>Humans</subject><subject>Lennox Gastaut Syndrome - drug therapy</subject><subject>Lennox–Gastaut syndrome</subject><subject>Neurology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rufinamide</subject><subject>Treatment Outcome</subject><subject>Triazoles - administration & dosage</subject><subject>Triazoles - adverse effects</subject><subject>Young Adult</subject><issn>1059-1311</issn><issn>1532-2688</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFUsuO1DAQtBCIXRY-AeQjlwQ_4tjhAFotsIw0EkjA2TJ2h_WQ2IPtsAwnLnwBf8iX4NHMcuDCySV3Vbe6qhF6SElLCe2fbNoM_vuSoGWEypawlhB1C51SwVnDeqVuV0zE0FBO6Qm6l_OGEDJ0lN9FJ0wx1ZFOnKKfL2L24RO2MWTvIJniK8JjTDgtow9mrr_YB7ytFQgl42tfrvAaQojffv_4dWlyMUvBeRdcijM8xW-vTAa8Wq1wSd5MOEFepqozwVVspuY6pslhO_ngba07U8x9dGc0U4YHx_cMfXj18v3F62b95nJ1cb5ubNfL0gwwUgOuU7KTwyCg5072EpxRYmRCCUrBWcL4yAc3SC6MGZ0SQKwbiSDO8DP0-NB3m-KXBXLRs88WpskEiEvWVMleUUl6VqniQLUp5pxg1NvkZ5N2mhK9T0Bv9DEBvU9AE6ZrAlX36Dhi-TiD-6u6sbwSnh8IUBf96iHpbKuzFpxPYIt20f93xLN_OtyY-Rl2kDdxSaG6qKnOVaDf7c9gfwVUckJZL_kfa0Wyww</recordid><startdate>20170401</startdate><enddate>20170401</enddate><creator>Kothare, Sanjeev</creator><creator>Kluger, Gerhard</creator><creator>Sachdeo, Rajesh</creator><creator>Williams, Betsy</creator><creator>Olhaye, Omar</creator><creator>Perdomo, Carlos</creator><creator>Bibbiani, Francesco</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170401</creationdate><title>Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data</title><author>Kothare, Sanjeev ; Kluger, Gerhard ; Sachdeo, Rajesh ; Williams, Betsy ; Olhaye, Omar ; Perdomo, Carlos ; Bibbiani, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c467t-9ef1aed48747995e63d767eda85f258511edc023f39d9735aafd85e0cdf050da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Anticonvulsants - administration & dosage</topic><topic>Anticonvulsants - adverse effects</topic><topic>Antiepileptic drug</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Dose-Response Relationship, Drug</topic><topic>Dosing</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Epilepsy</topic><topic>Humans</topic><topic>Lennox Gastaut Syndrome - drug therapy</topic><topic>Lennox–Gastaut syndrome</topic><topic>Neurology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rufinamide</topic><topic>Treatment Outcome</topic><topic>Triazoles - administration & dosage</topic><topic>Triazoles - adverse effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kothare, Sanjeev</creatorcontrib><creatorcontrib>Kluger, Gerhard</creatorcontrib><creatorcontrib>Sachdeo, Rajesh</creatorcontrib><creatorcontrib>Williams, Betsy</creatorcontrib><creatorcontrib>Olhaye, Omar</creatorcontrib><creatorcontrib>Perdomo, Carlos</creatorcontrib><creatorcontrib>Bibbiani, Francesco</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seizure (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kothare, Sanjeev</au><au>Kluger, Gerhard</au><au>Sachdeo, Rajesh</au><au>Williams, Betsy</au><au>Olhaye, Omar</au><au>Perdomo, Carlos</au><au>Bibbiani, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data</atitle><jtitle>Seizure (London, England)</jtitle><addtitle>Seizure</addtitle><date>2017-04-01</date><risdate>2017</risdate><volume>47</volume><spage>25</spage><epage>33</epage><pages>25-33</pages><issn>1059-1311</issn><eissn>1532-2688</eissn><abstract>Highlights • Rufinamide is an effective treatment option for Lennox–Gastaut syndrome. • Low starting doses and slow titration may improve rufinamide tolerability. • Clinical experience supports starting rufinamide at a dose of 5–10 mg/kg/day. • Real-world data show the dose can be escalated to 15–20 mg/kg/day after 1–3 days. • The authors recommend not increasing rufinamide dose if no response is noted.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28284045</pmid><doi>10.1016/j.seizure.2017.02.008</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1059-1311 |
| ispartof | Seizure (London, England), 2017-04, Vol.47, p.25-33 |
| issn | 1059-1311 1532-2688 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1876817062 |
| source | ScienceDirect Freedom Collection |
| subjects | Adolescent Adult Anticonvulsants - administration & dosage Anticonvulsants - adverse effects Antiepileptic drug Child Child, Preschool Clinical Trials, Phase III as Topic Dose-Response Relationship, Drug Dosing Double-Blind Method Drug Administration Schedule Epilepsy Humans Lennox Gastaut Syndrome - drug therapy Lennox–Gastaut syndrome Neurology Randomized Controlled Trials as Topic Rufinamide Treatment Outcome Triazoles - administration & dosage Triazoles - adverse effects Young Adult |
| title | Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T23%3A40%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dosing%20considerations%20for%20rufinamide%20in%20patients%20with%20Lennox%E2%80%93Gastaut%20syndrome:%20Phase%20III%20trial%20results%20and%20real-world%20clinical%20data&rft.jtitle=Seizure%20(London,%20England)&rft.au=Kothare,%20Sanjeev&rft.date=2017-04-01&rft.volume=47&rft.spage=25&rft.epage=33&rft.pages=25-33&rft.issn=1059-1311&rft.eissn=1532-2688&rft_id=info:doi/10.1016/j.seizure.2017.02.008&rft_dat=%3Cproquest_cross%3E1876817062%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c467t-9ef1aed48747995e63d767eda85f258511edc023f39d9735aafd85e0cdf050da3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1876817062&rft_id=info:pmid/28284045&rfr_iscdi=true |